Atossa Therapeutics (ATOS) announced it has requested a Type C meeting with the U.S. Food and Drug Administration, FDA, to discuss a regulatory strategy aimed at accelerating development of low-dose (Z)-endoxifen for breast cancer risk reduction. Atossa is a clinical-stage biopharmaceutical company developing new approaches in breast cancer treatment and risk-reduction, commonly termed prevention of breast cancer.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATOS:
- Atossa Therapeutics Receives Nasdaq Non-Compliance Notice
- Atossa selects PSI for Z-endoxifen monotherapy study
- Buy Rating for Atossa Therapeutics: Strong Financials and Promising Endoxifen Developments
- Atossa Therapeutics Advances Breast Cancer Treatments
- Positive FDA Feedback and Promising Phase 2 Results Justify Buy Rating for Atossa Therapeutics